financetom
Business
financetom
/
Business
/
Oppo K1 with fingerprint scanner, 25-megapixel selfie camera, launched in India at Rs 16,990
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oppo K1 with fingerprint scanner, 25-megapixel selfie camera, launched in India at Rs 16,990
Feb 6, 2019 9:18 AM

Chinese phone maker Oppo on Wednesday introduced K-series in Indian market, with the launch of Oppo K1.

Considered as the cheapest smartphone with an in-display fingerprint sensor in India, Oppo K1 comes with 64GB storage, 4GB RAM and is priced at Rs 16,990.

Oppo K1 will be exclusively available via Flipkar from February 12, 2019 in Piano Black and Astral Blue colour options.

The device is powered by Qualcomm Snapdragon 660SoC, features a 6.4-inch full HD+ (2340×1080 pixels) display, with a dual-camera setup that includes a 16-megapixel primary sensor, 2-megapixel secondary sensor and 25-megapixel front camera.

The dual-SIM smartphone runs on Android 8.1 Oreo-based ColorOS 5.2 and is packed with a 3,600mAh battery.

First Published:Feb 6, 2019 6:18 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
Jan 28, 2025
Jan 28 (Reuters) - QMSK Technology Co Ltd: * QMSK TECHNOLOGY CO LTD: FILES FOR U.S. IPO * QMSK TECHNOLOGY CO., LTD: EXPECT IPO OFFERING PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE * QMSK TECHNOLOGY CO: EXPECT US IPO PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE...
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Jan 28, 2025
Jan 28 (Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes. Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same...
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Jan 28, 2025
Benchmark analyst Cody Acree named Tower Semiconductor ( TSEM ) Inc. among recommended oversold names following Monday’s market rout, which was triggered by DeepSeek’s announcement of its advanced language model. Monday’s Selloff: Chinese AI lab DeepSeek unveiled a new large language model reportedly meeting or exceeding leading competitors’ performance at a fraction of the cost. The claims, though met with...
Market Chatter: Nvidia Short Sellers Amass $6.6 Billion in Profits Amid Frenzy Over DeepSeek
Market Chatter: Nvidia Short Sellers Amass $6.6 Billion in Profits Amid Frenzy Over DeepSeek
Jan 28, 2025
03:06 PM EST, 01/28/2025 (MT Newswires) -- Bets against Nvidia ( NVDA ) amid a surge in interest for Chinese artificial intelligence app DeepSeek yielded one-day gains of about $6.6 billion for short sellers, Reuters reported Tuesday, citing data analytics firm Ortex. Short positions in Broadcom ( AVGO ) resulted in more than $2 billion in profits, the report added....
Copyright 2023-2025 - www.financetom.com All Rights Reserved